Abstract
Introduction
Human gliomas are the most frequent primary tumours of the central nervous system. Because nearly half of them are malignant, their treatment represents one of the most formidable challenges in clinical medicine. Over the past two decades, the overall survival rate of patients with gliomas has hardly improved, with only ~2% of patients aged 65 years or older survived for more than 2 years [1, 2] . Therefore, new diagnostic and therapeutic strategies are needed to control this devastating disease.
Recently, considerable progress has been made in understanding the genetic alterations that are associated with gliomas, which involve both oncogenes and tumour suppressor genes [3] . We previously reported that one of the newly described tumour suppressor genes, designated programmed cell death 4 (PDCD4), was silenced in the vast majority of human gliomas, 77% at protein level and 47% at mRNA level [4] . PDCD4, or MA3, was first cloned as a gene whose expression was elevated in mouse cell lines undergoing apoptosis [5] . Its homologues of human (H731; TIS), chicken and rat (DUG) were soon described [6] [7] [8] [9] [10] [11] . Consequently, PDCD4-deficient mice develop spontaneous tumours of the lymphoid origin [12] , and PDCD4 transgenic mice showed significant resistance to tumour induction [13] . Furthermore, PDCD4 exerted its anti-tumour roles via regulating signal transduction pathways [14, 15] . Human PDCD4 was first cloned from a human glioma library, which is highly homologous to the mouse PDCD4 [16] . PDCD4 is expressed ubiquitously in normal tissues, but its loss or reduction was found in several types of human cancer cell lines [17] , and some primary tumours such as human gliomas [4] , lung cancer [18] , hepatocellular carcinomas [19] and pancreatic cancer [20] . may posttranscriptionally regulate PDCD4 expression in colorectal cancer [21] . Dorrello et al. find that S6K1 and betaTRCP may control the levels of PDCD4 protein through an ubiquitination-dependent mechanism [22] . However 
. Previous studies have shown that PDCD4 directly interacts with the eukaryotic initiation factor (eIF) 4A complex to inhibit protein translation. It prevents tumour transformation in the mouse JB6 model system through inhibiting activating protein 1 (AP-1) function

Materials and methods
Tumour specimens and cell lines
A total of 84 glioma specimens including 30 frozen [4] 
RNA isolation and RT-PCR
SDS-PAGE and Western blot
The proteins were extracted from tissue samples and glioma cell lines using a modified TRIzol ® one-step extraction method [26, 27] 
Methylation-specific PCR (MSP)
5-aza-2Ј-deoxycytidine treatment
Results
Methylation of the PDCD4 5ЈCpG island is common in glioma cell lines and primary gliomas
Of the 30 frozen glioma samples examined previously, 47% (14/30) of them lacked the PDCD4 mRNA expression [4] . However, the mechanisms of the PDCD4 silencing at mRNA levels are unclear. 5ЈCpG island methylation is a common epigenetic mechanism implicated in the silencing of tumour suppressor genes in human cancers [24] . Fig. 2A) . 
To further confirm the status of demethylation, the PCR products were also sequenced after the treatment of high concentration 5-aza-2Ј-deoxycytidine. The methylated sites disappeared in both glioma cell lines (data not shown). Remarkably, blocking methylation resulted in a substantial restoration of PDCD4 expression at both mRNA (Fig. 2B) and protein levels (Fig. 2C and D). Of note is that although two bands appeared in the PDCD4 PCR products of treated U251 cell line, only the upper band was PDCD4 specific as confirmed by sequencing. These results indicated that PDCD4 silencing at mRNA level in glioma cells was predominantly caused by 5ЈCpG island methylation.
Restoration of PDCD4 expression in glioma cells inhibited their proliferation, induced their apoptosis and prevented their colony formation
The frequent loss of PDCD4 expression in glioma cells suggests that PDCD4 may inhibit the proliferation of gliomas. To determine the effect of PDCD4 on the growth and survival of glioma cells, a
recombinant pDsRed plasmid carrying the full-length PDCD4 cDNA was transfected into PDCD4 -U251 and U87 glioma cells.
Forty-eight hours later, both the fluorescent marker and PDCD4
were detected in the glioma cells (Fig. 3A and B) . Importantly, PDCD4 expression in these cells significantly inhibited their growth, compared with untransfected control and mock-transfected groups (Fig. 3C and D (Fig. 3F ). (Fig. 4) 
Glioma cells, unlike normal glia cells, have the tendency to form colonies in the culture
PDCD4 expression in human primary glioma tissues improved the prognosis of patients with high-grade gliomas
The above results showed that restoration of PDCD4 expression inhibited proliferation and prevented colony formation of cell lines in vitro. To determine whether PDCD4 expression in primary Table 1 ). The expression of PDCD4 in gliomas from male patients was significantly higher than that from female patients (P ϭ 0.0245).
De-methylation status of the PDCD4 CpG island was detected by methylationspecific PCR; M, methylated; U, unmethylated (A). The expression of PDCD4 at 48 hrs was examined by RT-PCR (B), Western blot (C) and immunocytochemistry (D). Normal brain tissue (normal) not treated with Doc was used as a control.
Discussion
In [17, 30] . Furthermore, loss or reduction of PDCD4 expression was detected in human primary tumour tissues including lung cancer [18] , hepatocellular carcinomas [19] and pancreatic cancer [20] . However, to date, the mechanism of PDCD4 silence in tumours is unclear.
Hypermethylation in 5ЈCpG island has been found in many tumours, which is often associated with the inactivation of cancerrelated genes such as p16 [31, 32] , PTEN [33] and EMP3 [34] [37, 38] . We found that reintroduction of PDCD4 in glioma cell lines could also induce their apoptosis and block cell cycle progression (see Fig. 3E and F) 
